Novo Nordisk drops about 2% as Wegovy launches in Germany
Novo Nordisk fell about 2% to $46.625 on Friday as Wegovy’s once-daily oral pill rollout reached its first EU market, with Germany joining markets that already sell the treatment.
Novo Nordisk NYSE:NVO, the diabetes-and-obesity heavyweight, fell approximately 2% to $46.625 Friday as Wegovy's pill rollout reached its first European Union market.
Germany now joins the United States, Britain and the United Arab Emirates in selling the once-daily oral weight-loss treatment.Germa…